Pituitary Complications of Checkpoint Inhibitor Use
Authors:
- 13 July 2024
- journal article
- review article
- Published by The Endocrine Society in Endocrinology
- Vol. 165 (9)
Abstract
Immune checkpoint inhibitors have revolutionized cancer therapy but are associated with a risk of endocrine immune-related adverse events, including pituitary complications. Autoimmune hypophysitis, traditionally a rare diagnosis, has become a more frequently encountered clinical entity with the emergence of antitumor immunotherapy. This mini-review aims to consolidate current knowledge, encompassing the epidemiology, pathophysiology, clinical presentation, diagnosis, and management of pituitary complications of immune checkpoint inhibitor use.Keywords
This publication has 57 references indexed in Scilit:
- Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant MelanomaJAMA Network Open, 2022
- Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndromeCancer Immunology, Immunotherapy, 2021
- Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS databaseJournal of Neuro-Oncology, 2021
- Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta‐Analysis and Systematic ReviewThe Journal of Clinical Pharmacology, 2020
- Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor DrugsJAMA Network Open, 2020
- Hypophysitis: An update on the novel forms, diagnosis and management of disorders of pituitary inflammationBest Practice & Research Clinical Endocrinology & Metabolism, 2019
- Hypothalamitis and severe hypothalamic dysfunction associated with anti–programmed cell death ligand 1 antibody treatmentEuropean Journal of Cancer, 2018
- High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanomaCancer, 2018
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor RegimensJAMA Oncology, 2018
- Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 BlockadeThe American Journal of Pathology, 2016